Early Metformin Initiation and Glycemic Outcomes in Gestational Diabetes: A Secondary Analysis of a Randomized Clinical Trial.
David Alberto Aguilar Macías, Alberto Alvarez-Iglesias, John M Ferguson et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of a double-masked, placebo-controlled randomized clinical trial assessed early metformin versus placebo, alongside usual care, in pregnancies complicated by gestational diabetes at two Irish centres. Generalized pairwise comparisons combined insulin initiation and fasting hyperglycemia at gestational weeks 32 and 38. Among 526 pregnancies with outcome data, the prioritized composite favored metformin (win ratio, 1.46 [95% CI, 1.13-1.89]; P = .004). The largest separation was for insulin initiation, also favoring metformin. The analysis offers an alternative, clinically ordered interpretation of treatment effects rather than replacing the trial’s original primary analysis.
Key findings
- Prioritized comparisons favored metformin for the composite outcome: win ratio, 1.46 [95% CI, 1.13-1.89]; P = .004.
- Insulin initiation showed the largest separation, favoring metformin (win ratio, 1.68 [95% CI, 1.19-2.38]; P = .003).
- Nonprioritized overall comparisons also favored metformin (win ratio, 1.53 [95% CI, 1.16-2.01]; P = .002).
Why it matters
Composite outcomes can obscure which components drive an apparent treatment effect. By ordering outcomes according to clinical priority and also examining them without prioritization, this analysis provides complementary ways to interpret metformin’s effects across insulin use and fasting hyperglycemia. The approach may also help inform how outcomes are selected and analyzed in future gestational diabetes trials.
What to keep in mind
This was a secondary analysis, so its findings complement rather than replace the original trial’s primary analysis. The study was conducted at two centres in Ireland, which may limit generalizability.